Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
10 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02406092 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | completed | Phase 3 | 139 | Hoffmann-La RocheINDUSTRY | 3 | Nov 21, 2024 | clinicaltrials |
| NCT03447132 | Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant(SAFIA) | completed | Phase 3 | 354 | International Cancer Research Group, United Arab EmiratesOTHER | 8 | Mar 10, 2023 |
| clinicaltrials |
| NCT03413579 | Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom(CIMAHOPE) | completed | Phase 3 | 37 | El Kendi Pharmaceuticals Manufacturing CompanyINDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01459328 | Resource-Sparing Curative Treatment for Rectal Cancer | unknown | Phase 3 | 350 | International Atomic Energy AgencyOTHER_GOV | 11 | Oct 25, 2011 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials